P2195 Safety and pharmacokinetics of i.v. azidothymidine alone and combined with colistin being developed for the treatment of carbapenem - and colistin- resistant Enterobacteriaceae (phase-1-study)
Azidothymidine (AZT) in combination with colistin (COL) has in vitro synergistic activity against COL-susceptible and -resistant and carbapenem-resistant Enterobacteriaceae(CRE), including mcr-1-producing Escherichia coli strains. In this phase-1 study the safety, tolerability and pharmacokinetics of IV-administration of AZT and colistimethate sodium(CMS) alone and co-administered were assessed in healthy male and female volunteers.
Click here to read the full paper
Helperby Therapeutics announces study results active against the WHO Critical Priority Carbapenem resistant bacterial pathogens